Clinical outcomes of everolimus in patients with hormone receptor positive breast cancer: a real-world analysis
For patients with HR+/HER2- advanced breast cancer, everolimus combined with endocrine therapy may serve as an alternative option after disease progression on CDK4/6 inhibitors.
Authors
- Lijun Di
- Ying Yan (ORCID: https://orcid.org/0000-0001-8556-7417)
- Xinyu Gui (ORCID: https://orcid.org/0000-0002-0589-8732)
- Guohong Song (ORCID: https://orcid.org/0000-0002-8696-1149)
- Yuhong Liu (ORCID: https://orcid.org/0000-0001-6771-011X)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1080/14796694.2025.2567485
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00